Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Anus Neoplasms 1

Interventions

Paclitaxel 11Fluorouracil 10pembrolizumab 9Cisplatin 9Radiotherapy 7Carboplatin 6Esophagectomy 5Nivolumab 4Drug Therapy 4Radiotherapy, Intensity-Modulated 3Leucovorin 3Chemoradiotherapy 3Cetuximab 3Capecitabine 3durvalumab 2atezolizumab 2Oxaliplatin 2Ipilimumab 2spartalizumab 1sintilimab 1selinexor 1regorafenib 1prexasertib 1osimertinib 1niraparib 1nilotinib 1nedaplatin 1nanocis 1fludarabine 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × ON 01910 × Gastrointestinal × Clear all
NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

Phase 2 Completed
64 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡